PainReform (PRFX) Competitors $1.86 -0.11 (-5.58%) Closing price 03:58 PM EasternExtended Trading$1.86 -0.01 (-0.27%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. PRPH, LPTX, MEIP, ALVR, FLGC, GELS, VYNE, AIMD, EDSA, and SYBXShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include ProPhase Labs (PRPH), Leap Therapeutics (LPTX), MEI Pharma (MEIP), AlloVir (ALVR), Flora Growth (FLGC), Gelteq (GELS), VYNE Therapeutics (VYNE), Ainos (AIMD), Edesa Biotech (EDSA), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors ProPhase Labs Leap Therapeutics MEI Pharma AlloVir Flora Growth Gelteq VYNE Therapeutics Ainos Edesa Biotech Synlogic ProPhase Labs (NASDAQ:PRPH) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts prefer PRPH or PRFX? PainReform has a consensus target price of $8.00, indicating a potential upside of 330.11%. Given PainReform's stronger consensus rating and higher possible upside, analysts plainly believe PainReform is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, PRPH or PRFX? PainReform has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$5.85M2.35-$16.78M-$1.26-0.26PainReformN/AN/A-$9.34M-$147.33-0.01 Does the MarketBeat Community favor PRPH or PRFX? ProPhase Labs received 111 more outperform votes than PainReform when rated by MarketBeat users. However, 75.00% of users gave PainReform an outperform vote while only 48.93% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformProPhase LabsOutperform Votes11448.93% Underperform Votes11951.07% PainReformOutperform Votes375.00% Underperform Votes125.00% Which has more risk & volatility, PRPH or PRFX? ProPhase Labs has a beta of -0.43, suggesting that its stock price is 143% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Do institutionals and insiders believe in PRPH or PRFX? 9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer PRPH or PRFX? In the previous week, ProPhase Labs had 1 more articles in the media than PainReform. MarketBeat recorded 2 mentions for ProPhase Labs and 1 mentions for PainReform. PainReform's average media sentiment score of 1.87 beat ProPhase Labs' score of 0.29 indicating that PainReform is being referred to more favorably in the news media. Company Overall Sentiment ProPhase Labs Neutral PainReform Very Positive Is PRPH or PRFX more profitable? PainReform has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. ProPhase Labs' return on equity of -62.92% beat PainReform's return on equity.Company Net Margins Return on Equity Return on Assets ProPhase Labs-217.64% -62.92% -30.22% PainReform N/A -450.64%-241.33% SummaryPainReform beats ProPhase Labs on 10 of the 16 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.74M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.018.5527.1919.64Price / SalesN/A262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book0.026.536.974.60Net Income-$9.34M$143.48M$3.23B$248.06M7 Day Performance-9.71%0.20%-0.88%-1.02%1 Month Performance-3.12%10.93%7.81%3.51%1 Year Performance-15.49%2.46%31.53%12.68% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform2.7239 of 5 stars$1.86-5.6%$8.00+330.1%-36.3%$3.74MN/A-0.014Positive NewsPRPHProPhase Labs1.2545 of 5 stars$0.37+1.1%N/A-92.9%$15.52M$5.85M-0.30130Short Interest ↑Gap DownLPTXLeap Therapeutics2.7146 of 5 stars$0.36-5.2%$4.92+1,271.5%-80.5%$14.86MN/A-0.1940Positive NewsGap DownMEIPMEI Pharma1.6912 of 5 stars$2.22-0.9%N/A-21.3%$14.79M$65.30M-0.39100News CoveragePositive NewsShort Interest ↑Gap DownALVRAlloVirN/A$2.90-2.0%N/A-84.0%$14.63MN/A-0.14110News CoverageGap UpFLGCFlora Growth2.7247 of 5 stars$0.64-4.5%$4.00+525.0%-30.7%$14.44M$53.26M-0.65280Positive NewsGap DownGELSGelteqN/A$1.50-6.3%N/AN/A$14.16MN/A0.00N/AVYNEVYNE Therapeutics2.4975 of 5 stars$0.93-2.3%$6.25+573.5%-58.6%$14.12M$605K-1.0830Short Interest ↑High Trading VolumeAIMDAinos1.3676 of 5 stars$0.63-6.5%N/A-35.5%$14.02M$106.21K-0.4940Positive NewsGap DownEDSAEdesa Biotech3.3511 of 5 stars$1.99+1.5%$21.00+955.3%-56.3%$13.98MN/A-1.0620Positive NewsShort Interest ↓SYBXSynlogic1.2732 of 5 stars$1.19+3.7%N/A-24.5%$13.94M$8K-0.2980Upcoming EarningsShort Interest ↑Gap Up Related Companies and Tools Related Companies PRPH Competitors LPTX Competitors MEIP Competitors ALVR Competitors FLGC Competitors GELS Competitors VYNE Competitors AIMD Competitors EDSA Competitors SYBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRFX Stock Free PRFX Stock Alerts